H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $29 from $24 and keeps a Buy rating on the shares after the company announced its intention to enter into a Medicaid National Drug Rebate agreement. This strategic move is prudent given that it could not only aid in accessing a larger patient base but also help in achieving sustainable growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Announces 2025 Financial Guidance
- Delcath Systems sees FY25 revenue $94M-$98M, consensus $94.47M
- Delcath Systems to enter Medicaid National Drug Rebate Agreement
- Delcath Systems Shareholders Approve Key Amendments at Meeting
- Delcath Systems: Strong Revenue Growth and Strategic Expansion Drive Buy Rating